Research and Real-world Outcomes Underscore Transpara Breast AI's Impact on Cancer Detection and Breast Imaging Workflow

CHICAGO, Nov. 30, 2025 /PRNewswire/ -- ScreenPoint Medical is showcasing the industry-leading Transpara Breast AI suite, an integrated set of solutions that includes Detection, Density, and Temporal Comparison at the 111^th Annual Radiological Society of North America (RSNA) Annual Meeting, November 30-December 4, 2025 (South Hall #4719). The most clinically validated Breast AI on the market, Transpara Breast AI is built for enterprise workflows to provide radiologists with a 'second pair' of eyes to help detect cancer earlier, reduce radiologist workload, and improve program performance.

2025 has been a pivotal year for ScreenPoint Medical. Surpassing 11 million mammograms processed, Transpara Breast AI is deployed in over 30 countries at leading healthcare providers and has been selected by 40% of the 2025 US News and World Report's Top 20 Best Hospitals Honor Roll recipients.

Additionally, Transpara Breast AI has been chosen in to be part of the only randomized controlled trials (RCTs) in the field of Breast AI: the MASAI RCT in Sweden and the upcoming $16mil PRISM RCT in the United States, which will commence in early 2026 and is spearheaded by researchers at UCLA and UC Davis. Results from MASAI published earlier this year found a 29% increase in cancer detection and a 44% decrease in screen-reading workload when using Transpara Detection compared to the standard of care.

Risk assessment is also a key theme at RSNA 2025: Transpara Risk, an image-based 5-year risk model for breast cancer,  and Transpara Detection are the subjects of a powerful new study, "Added Value of Breast Cancer Risk Prediction Versus Detection Over a Two-year Time Period with Mammography" (S5-SSBR02-4, Sunday, November 30, 2:30 PM, S406A). This research shows the added value of risk prediction for precision care, with Transpara solutions outperforming both RSNA CAD and Mirai. AI-based risk analysis supports ScreenPoint Medical's commitment to women worldwide by powering personalized prevention pathways and enabling earlier diagnosis for less invasive treatment. Transpara Risk is approved for investigational use only.

In addition to Sunday's session, the clinical and workflow benefits of Transpara Breast AI are the subject of notable presentations and posters throughout the week at RSNA:

• The study, "Comparing Four Commercial AI Algorithms for Standalone Breast Cancer Detection on Digital Breast Tomosynthesis in a Dutch Population-based Screening Cohort" (T3-SSBR05-6, Tuesday, December 2, 9:30 AM, S406A) is the first study to compare commercial AI algorithms for screening DBT on the same large dataset. The results showed significant differences in performance between some of the four commercial AI algorithms with Transpara Detection outperforming the competition. 
• The poster, "Potential of Artificial Intelligence to Detect Interval Breast Cancers" (M5A-SPBR, Monday, December 1, 12:15 PM, Learning Center) suggests that Transpara Detection may have facilitated earlier detection of 38% of interval breast cancers, especially those missed or underestimated by radiologists. Research conducted at Johns Hopkins Medicine.
• The study, "Use of Multiple Prior Exams Improves Specificity of an AI System for Breast Cancer Detection in a Retrospective Multi-site Validation" (T3-SSBR05, Tuesday, December 2, 9:30 AM, S406A) finds that Transpara Breast AI achieves a higher specificity when using prior exams for analysis.
• The poster, "Real-World Performance of an FDA-approved Artificial Intelligence Tool for Screening Mammography" (W5B-SPBR-3, Wednesday, December 3, 12:45 PM, Learning Center) shows early positive results of clinical adoption into a busy screening mammography practice. Transpara Detection demonstrated strong performance in stratifying cancer risk and supporting recall decisions. Research conducted at Johns Hopkins Medicine.
• The study, "AI Pre-reading of Digital Breast Tomosynthesis: A Multi-site Validation of a Novel Imaging Biomarker for Confident Identification of Normal DBT Examinations" (R1-SSBR10, Thursday, December 4, 8:00 AM, S406A), showed that a novel AI-driven imaging biomarker for pre-reading of DBT can confidently identify approximately one-third of normal DBT screening exams with a negative predictive value nearing 100%. This may enable pre-reading in screening, potentially allowing radiologists to accelerate the reading of this group of DBT exams, safely improving radiologist efficiency and reducing workload.

"We believe that research drives real-world results. The groundbreaking research presented at RSNA 2025 this week as well as our ongoing research across breast imaging RCTs support the reality that Transpara Breast AI is elevating the standard of care" said Pieter Kroese, CEO of ScreenPoint Medical. "Our partners, our performance, and our product are the reasons healthcare leaders consistently choose Transpara Breast AI. We look forward to fruitful dialogue and forward momentum at radiology's leading conference."

To discover more about the leading Breast AI solutions on the market, visit Booth #4719 (South Hall) at RSNA 2025 or schedule an online product overview after the show at https://screenpoint-medical.com

About ScreenPoint Medical 

In the fight against breast cancer, every image is an opportunity: to unlock insight, to uncover risk, to embody health, to empower life. We build AI-powered technology for every step of the breast imaging continuum, improving consistency, reducing uncertainty, enhancing patient experience, and translating opportunity into tangible outcomes.

Proven through research, driven by innovation, and tailor-made for those seeking to lead in breast health, ScreenPoint's Transpara Breast AI is trusted by radiologists and women across the globe. We are Breast AI. Learn more at https://screenpoint-medical.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/screenpoint-medical-showcases-transpara-breast-ai-suite-at-rsna-2025-302628631.html

SOURCE ScreenPoint Medical